Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741094 | 0.83 | BRD4 (0.38) | QPCTSIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL19159359 | 0.81 | HTR2A (0.45) | QPCTHTR2AHTR2CHTR2BKMO | |
| SCHEMBL6744650 | 0.79 | PTGER3 (0.41) | KMOKDM4ETSHRMAPK1SYK | |
| SCHEMBL6741339 | 0.76 | HRH3 (0.50) | SIGMAR1MCHR1MCHR2 | |
| SCHEMBL6746000 | 0.74 | HRH3 (0.40) | QPCTSIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6740873 | 0.73 | KMO (0.39) | QPCTHTR2AHTR2CHTR2BKMO | |
| SCHEMBL13132364 | 0.73 | ITK (0.43) | HTR2AHTR2CHTR2BKMOMAPK1 | |
| SCHEMBL6739781 | 0.70 | KMO (0.56) | QPCTHTR2AHTR2CHTR2BKMO | |
| SCHEMBL20769975 | 0.68 | HTR2A (0.50) | HTR2AHTR2CHTR2BKMOKDM4E | |
| SCHEMBL8430529 | 0.68 | KMO (0.64) | HTR2AHTR2CHTR2BKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | QPCT 954/4885TMEM97 1382/4885SIGMAR1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.